{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T08:08:37Z","timestamp":1789373317516,"version":"build-2803163510"},"reference-count":32,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Gilead Sciences","award":["The meetings and workshops of the working group"],"award-info":[{"award-number":["The meetings and workshops of the working group"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["AIDS Patient Care and STDs"],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:p>\n                    Despite progress in antiretroviral therapy and prevention, HIV remains a major public health challenge in Spain. Pre-exposure prophylaxis (PrEP) is a proven and effective prevention strategy, but challenges in access, equity, adherence and persistence limit its population impact. Our aim was to identify current barriers to PrEP adoption in Spain and develop actionable solutions. We conducted a structured consensus process (September 2024\u2013May 2025) with 19 experts from fields including infectious diseases\/HIV care, sexual health\/sexually transmitted infection services, primary care, emergency medicine, nursing, pediatrics, hospital pharmacy, public health, epidemiology\/biostatistics, and community-based organizations. It included semi-structured interviews, multidisciplinary small-group sessions, and two plenary workshops. Complementary descriptive surveys of healthcare professionals (HCPs) and NGO\/community health centers (\n                    <jats:italic toggle=\"yes\">n<\/jats:italic>\n                    = 150) and current\/potential\/past PrEP users (\n                    <jats:italic toggle=\"yes\">n<\/jats:italic>\n                    = 95) provided contextual data. Consensus statements were developed using a facilitator-led approach based on nominal group techniques, with community representatives contributing lived-experience insights. The panel identified key challenges, including fragmented access (hospital-centered), capacity constraints, restrictive eligibility criteria, knowledge gaps, adherence and persistence issues, and limitations in information systems. To address these, a focused decalogue was developed to promote decentralization, equity, person-centered care and preparedness for transformative innovation in PrEP. The ComPrEmetidos consensus offers an operational roadmap to move Spain from policy availability to program performance and more effectively reduce new HIV infections in Spain. Priorities include decentralization, improving the training and knowledge of HCPs and the general public, rapid linkage to PrEP, and the incorporation of innovation, especially for those for whom oral PrEP is not sufficient.\n                  <\/jats:p>","DOI":"10.1177\/10872914261472566","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T07:10:16Z","timestamp":1785913816000},"page":"391-400","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["ComPrEmetidos: A Multidisciplinary Consensus to Transform HIV Prevention in Spain"],"prefix":"10.1177","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7485-2252","authenticated-orcid":false,"given":"Inmaculada","family":"Jarr\u00edn","sequence":"first","affiliation":[{"name":"CoRIS Coordination Unit, National Center for Epidemiology and CIBER of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8958-6441","authenticated-orcid":false,"given":"Nuria","family":"Fernandez","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, IdISSC, Hospital Cl\u00ednico San Carlos, Sandoval Health Center, Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Garrido","sequence":"additional","affiliation":[{"name":"Apoyo Positivo, Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"L\u00f3pez","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Vall d\u2019Hebron University Hospital, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Polo","sequence":"additional","affiliation":[{"name":"Specialist in Internal Medicine\/Infectious Diseases, Coordinator of the Study Group on Metabolic Disorders and Comorbidities in HIV (GEAM), Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the ComPrEmetidos Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"e_1_3_4_2_1","unstructured":"1.Onusida. Global AIDS Strategy 2021\u20132026. End Inequalities. End AIDS. UNAIDS; 2021. Available from: https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/global-AIDS-strategy-2021-2026_en.pdf [Last accessed: July31 2025]."},{"key":"e_1_3_4_3_1","unstructured":"2.Ministerio de Sanidad. Vigilancia epidemiol\u00f3gica del VIH y SIDA en Espa\u00f1a 2024. Actualizaci\u00f3n 30 de junio de 2025. Ministerio de Sanidad: Madrid Spain; 2025. Available from: https:\/\/www.sanidad.gob.es\/ciudadanos\/enfLesiones\/enfTransmisibles\/sida\/vigilancia\/docs\/Informe_VIH_SIDA_2024_Nov_2025.pdf [Last accessed: July31 2025]."},{"key":"e_1_3_4_4_1","unstructured":"3.Unidad de vigilancia del VIH ITS y hepatitis B y C. Actualizaci\u00f3n del Continuo de Atenci\u00f3n del VIH en Espa\u00f1a 2021. Centro Nacional de Epidemiolog\u00eda\u2014Instituto de Salud Carlos III\/Divisi\u00f3n de control de VIH ITS Hepatitis Virales y Tuberculosis\u2014Direcci\u00f3n General de Salud P\u00fablica: Madrid Spain; 2023. Available from: https:\/\/www.sanidad.gob.es\/ciudadanos\/enfLesiones\/enfTransmisibles\/sida\/vigilancia\/docs\/Continuo_atencion_VIH_mayo_2023.pdf [Last accessed: July31 2025]."},{"key":"e_1_3_4_5_1","unstructured":"4.Ministerio de Sanidad. Plan Estrat\u00e9gico para la Prevenci\u00f3n y Control de la Infecci\u00f3n por VIH y las ITS en Espa\u00f1a 2021\u20132030. Ministerio de Sanidad; 2021. Available from: https:\/\/www.sanidad.gob.es\/ciudadanos\/enfLesiones\/enfTransmisibles\/sida\/planNalSida\/Plan_de_Prevencion_y_Control1.pdf [Last accessed: July31 2025]."},{"key":"e_1_3_4_6_1","unstructured":"5.Centers for Disease Prevention and Control. Effectiveness of Prevention Strategies to Reduce the Risk of Acquiring or Transmitting HIV. CDC; 2022. Available from: https:\/\/www.cdc.gov\/hivpartners\/php\/riskandprevention\/index.html [Last accessed: July31 2025]."},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.70120"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011205"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1108524"},{"key":"e_1_3_4_10_1","unstructured":"9.Grupo de Trabajo de PrEP. Manual de implementaci\u00f3n de un Programa de Profilaxis Preexposici\u00f3n al VIH en Espa\u00f1a. Actualizaci\u00f3n diciembre de 2021. Divisi\u00f3n de Control de VIH I Hepatitis virales y Tuberculosis Ministerio de Sanidad; 2021. Available from: https:\/\/www.sanidad.gob.es\/ciudadanos\/enfLesiones\/enfTransmisibles\/sida\/PrEP\/Manual_PrEP_FINAL.pdf [Last accessed: July31 2025]."},{"key":"e_1_3_4_11_1","unstructured":"10.O\u2019Halloran C Sun S Nash S and Brown A. HIV in the United Kingdom: Towards Zero HIV Transmissions by 2030. Public Health England: London England; 2019."},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002790"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab263"},{"key":"e_1_3_4_14_1","unstructured":"13.Ministerio de Sanidad. Sistema de Informaci\u00f3n de los Programas de PrEP (SIPrEP) Informe de resultados noviembre 2019-mayo 2025. Ministerio de Sanidad; 2025. Available from: https:\/\/www.sanidad.gob.es\/ciudadanos\/enfLesiones\/enfTransmisibles\/sida\/PrEP\/Informe_SiPreP__septiembre2025.pdf [Last accessed: June6 2025]."},{"key":"e_1_3_4_15_1","unstructured":"14.Instituto de Salud Carlos III. SIPrEP Sistema de Informaci\u00f3n de Programas de Profilaxis Preexposici\u00f3n al VIH en Espa\u00f1a. Instituto de Salud Carlos III: Madrid Spain; 2024. Available from: https:\/\/siprep.isciii.es\/ [Last accessed: July28 2025]."},{"key":"e_1_3_4_16_1","unstructured":"15.European Centre for Disease Prevention and Control (ECDC). Pre-exposure prophylaxis for HIV prevention in Europe and Central Asia. Monitoring implementation of the Dublin Declaration on Partnership to fight HIV\/AIDS in Europe and Central Asia\u20132023 progress report. 2024. ECDC; 2024. Available from: https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/hiv-prevention-dublin-declaration-evidence-brief-2023.pdf [Last accessed: July28 2025]."},{"key":"e_1_3_4_17_1","unstructured":"16.European Centre for Disease Prevention and Control (ECDC). Progress towards reaching the Sustainable Development Goal 3.3 targets related to HIV tuberculosis viral hepatitis and sexually transmitted infections in the EU\/EEA: 2024 progress report (2022\u20132023 data). ECDC: Stockholm Sweden; 2024. Available from: https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/hiv-tuberculosis-hepatitis-sustainable-development-goal-progress-2024.pdf [Last accessed: July31 2025]."},{"key":"e_1_3_4_18_1","unstructured":"17.European Medicines Agency (EMA). Apretude. Cabotegravir. EMA: Amsterdam Netherlands; 2025. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/apretude [Last accessed: October23 2025]."},{"key":"e_1_3_4_19_1","unstructured":"18.Belza M Gonz\u00e1lez-Recio P Moreno-Garc\u00eda S Donat M and Iglesias A. Transaludes: salud en personas trans y\/o no binarias en Espa\u00f1a. Instituto de Salud Carlos III (ISCIII): Madrid Spain; 2024. Available from: https:\/\/repisalud.isciii.es\/entities\/publication\/a1702ded-a65d-4079-bf27-1cff0633e1e4 [Last accessed: June6 2025]."},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0260063"},{"key":"e_1_3_4_21_1","first-page":"S34","article-title":"An\u00e1lisis de la lista de espera para empezar PREP en BCN Checkpoint: dos a\u00f1os de espera y 20 personas seroconvierten antes de llegar su turno","volume":"43","author":"P\u00e9rez-Tejera F","year":"2025","unstructured":"20.P\u00e9rez-Tejera F, , Dalmau-Bueno A, , Saz J, , Rivero \u00c1, and Taboada H. An\u00e1lisis de la lista de espera para empezar PREP en BCN Checkpoint: dos a\u00f1os de espera y 20 personas seroconvierten antes de llegar su turno. Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica Exhibici\u00f3n de p\u00f3steres 2025;43:S34\u2013S128.","journal-title":"Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica Exhibici\u00f3n de p\u00f3steres"},{"key":"e_1_3_4_22_1","unstructured":"21.National AIDS Trust. UK HIV statistics. National AIDS Trust: London England; 2024. Available from: https:\/\/nat.org.uk\/about-hiv\/hiv-statistics\/ [Last accessed: September26 2025]."},{"key":"e_1_3_4_23_1","unstructured":"22.Ministere des Solidarites et de la Sante. National strategic roadmap for sexual health 2021\u20132024. Minist\u00e8re des Solidarit\u00e9s et de la Sant\u00e9: Paris France; 2021. Available from: https:\/\/sante.gouv.fr\/IMG\/pdf\/feuille_de_route_sante_sexuelle_2021-2024_16122021_eng-gb_final.pdf [Last accessed: September26 2025]."},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2022.100486"},{"key":"e_1_3_4_25_1","unstructured":"24.EPI-PHARE (ANSM-CNAM). Suivi de l\u2019utilisation de la prophylaxie pr\u00e9\u2010exposition (PrEP) au VIH. Actualisation des donn\u00e9es jusqu\u2019au 30 Juin 2024. EPI-PHARE (ANSM-CNAM): Saint-Denis France; 2024. Available from: https:\/\/www.epi-phare.fr\/rapports-detudes-et-publications\/prep-vih-2024\/ [Last accessed: July22 2025]."},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(12)70315-8"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31816e3971"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.70048"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(22)00106-2"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(22)00030-3"},{"key":"e_1_3_4_31_1","unstructured":"30.World Health Organization (WHO). Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. WHO; 2025. Available from: https:\/\/iris.who.int\/bitstream\/handle\/10665\/381892\/9789240111608-eng.pdf?sequence=1 [Last accessed: July23 2025]."},{"key":"e_1_3_4_32_1","unstructured":"31.World Health Organization (WHO). Guidelines on long-acting injectable cabotegravir for HIV prevention. WHO; 2022. Available from: https:\/\/iris.who.int\/bitstream\/handle\/10665\/360869\/9789240054097-eng.pdf?sequence=1 [Last accessed: July23 2025]."},{"key":"e_1_3_4_33_1","unstructured":"32.Gilead Sciences. European Commission Authorizes Twice-Yearly Yeytuo\u00ae (Lenacapavir) for HIV Prevention. Gilead Sciences; 2025. Available from: https:\/\/www.gilead.com\/news\/news-details\/2025\/european-commission-authorizes-twice-yearly-yeytuo-lenacapavir-for-hiv-prevention [Last accessed: August28 2025]."}],"container-title":["AIDS Patient Care and STDs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10872914261472566","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10872914261472566","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10872914261472566","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T07:58:38Z","timestamp":1789372718000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10872914261472566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"alternative-id":["10.1177\/10872914261472566"],"URL":"https:\/\/doi.org\/10.1177\/10872914261472566","relation":{},"ISSN":["1087-2914","1557-7449"],"issn-type":[{"value":"1087-2914","type":"print"},{"value":"1557-7449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]}}}